TORONTO and DALLAS, Oct. 2, 2026 /CNW/ -- Perimeter Medical Imaging AI, Inc. (TSX-V: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that Michelle Caron, CPA, has been appointed to its Board of Directors, effective immediately.

Adrian Mendes, Perimeter's Chief Executive Officer, stated, "We are thrilled to welcome Michelle to our Board. Her extensive finance leadership experience, including her current role as Chief Financial Officer of A10 Networks and her prior tenure across Danaher Corporation's life sciences businesses, will be a significant asset as we continue to scale our commercial operations and advance our AI-enabled Claire(TM) technology. We look forward to benefiting from her strategic counsel."

Ms. Caron commented, "I am excited to join Perimeter's Board at such a pivotal time in the Company's growth. I look forward to leveraging my financial and operational experience to support Perimeter's continued commercialization efforts and the advancement of its AI-enabled technology."

In a finance career spanning over 28 years, Ms. Caron currently serves as the Chief Financial Officer of A10 Networks, a Nasdaq-listed company delivering secure application and network solutions designed to protect, optimize, and scale business-critical systems across on-premises, hybrid cloud, and edge environments. Prior to joining A10 Networks, she was Chief Financial Officer at Beckman Coulter Life Sciences, having previously been Group Financial Officer of Pall and Chief Financial Officer of Phenomenex, all of which are operating companies or subsidiaries under parent organization, Danaher Corporation. Prior to joining Danaher, Ms. Caron worked at Philips Healthcare and Stryker Biotech in finance and controller roles. She is a Certified Public Accountant and earned her MBA from Southern Connecticut State University and her BSc in Accounting from Central Connecticut State University.

About Perimeter Medical Imaging AI, Inc.

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire(TM), recently approved by the U.S. Food and Drug Administration (FDA), is our next-generation AI-enabled device. The Company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Indications for Use: The Claire OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with physician interpretation of the images. The Claire OCT System is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.

The Claire OCT System should not be used to replace standard tissue histopathology assessment and should not be used for diagnosis. The device is not intended for use in any of the following individuals: under the age of 18, male, have metastatic cancer (Stage IV), have lobular carcinoma as their primary diagnosis, have had previous ipsilateral breast surgery for benign or malignant disease within two years (including implants and breast augmentation), patients with multi-centric disease (histologically diagnosed cancer in two different quadrants of the breast), unless resected in a single specimen, patients with bilateral disease (diagnosed cancer in both breasts), patients who are currently lactating, patients who are currently pregnant, or concurrent use in surgeries with cryo-assisted localization. Refer to prescriber labeling for full safety information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could, " "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter's S-Series and B-Series OCT systems, and Perimeter's ongoing clinical, regulatory, and commercialization activities, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis and Annual Information Form for the year ended December 31, 2025, which are available on Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

CONTACTS:

Stephen Kilmer

Investor Relations

Direct: 647-872-4849

Email: skilmer@perimetermed.com

Adrian Mendes

Chief Executive Officer

Toll-free: 888-988-7465 (PINK)

Email: investors@perimetermed.com

609137902v.1

View original content to download multimedia:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-appoints-finance-executive-michelle-caron-to-board-of-directors-302896717.html

SOURCE Perimeter Medical Imaging AI Inc.

Copyright CNW Group 2026